Clinical Trial Update: Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination [Phase 2]

View source ↗

Summary

A Phase 2 multicenter study evaluating the effectiveness and toxicity of Sorafenib (Nexavar) in adults with uveal melanoma and metastatic disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: University Hospital, Caen | Conditions: Uveal Melanoma | Phase 2 | Status: COMPLETED